TRANSPOD
22.7.2022 08:02:07 CEST | Business Wire | Press release
TransPod , the startup that is building the world’s leading ultra-high-speed ground transportation system (the TransPod Line ) to disrupt and redefine passenger and cargo transportation, unveiled the FluxJet, an industry-defining innovation that transforms the way we live, work, and travel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220721005004/en/
Based on groundbreaking innovations in propulsion and fossil-fuel-free clean energy systems, the FluxJet is a fully electric vehicle that is effectively a hybrid between an aircraft and a train. Featuring technological leaps in contactless power transmission and a new field of physics called veillance flux , the FluxJet travels in a protected guideway at over 1000 km/h – faster than a jet and three times as fast as a high-speed train.
The FluxJet will operate exclusively on the TransPod Line, a network system with stations in key locations and major cities, featuring high-frequency departures designed to enable fast, affordable, and safe travel. Most recently, TransPod confirmed $550M US finance and announced the next phase of an $18B US infrastructure project to build the TransPod Line to connect the cities of Calgary and Edmonton in Alberta, Canada. Preliminary construction work, including the environmental impact assessment, has begun. This critical project will create up to 140,000 jobs and add $19.2B to the region’s GDP throughout construction. Once the TransPod Line is in operation, it will cost passengers approximately 44 per cent less than a plane ticket to travel the corridor and reduce CO2 emissions by 636,000 tonnes per year.
“All the hard work over the past few years has led to this milestone moment where talk is becoming a reality. The technology is proven, and we have the confidence of investors, governments, and partners to continue pushing forward to redefine transportation effectively,” said Sebastien Gendron, co-founder and CEO, TransPod.
At TransPod’s unveiling event in Toronto, a scaled-down FluxJet was featured in a live demonstration showing its flight capabilities. The almost 1-tonne FluxJet vehicle demonstrated a take-off, travel, and landing procedure within its guideway. Event and demo footage can be found here .
“This milestone is a major leap forward,” said Ryan Janzen, co-founder and CTO, TransPod. “The FluxJet is at a nexus of scientific research, industrial development, and massive infrastructure to address passengers' needs and reduce our dependence on fossil-fuel-heavy jets and highways.”
“TransPod completely changes the game with ultra high-speed, zero-emission passenger travel and freight transportation between major gateway cities,” said Yung Wu, CEO of MaRS Discovery District. “It is time for bold action from our policymakers, investors, and operators to support the commercialization of made-in-Canada innovations like TransPod, to win in the multi-trillion dollar global innovation economy."
“The FluxJet is a first for Canadian innovation and is the next great infrastructure project to be brought worldwide,” said Janzen. “The TransPod Line is being developed in collaboration with our partners in Europe, USA, and beyond, including universities, research centres, the aerospace industry, architecture, railway, and construction partners.”
TransPod’s FluxJet unveiling was made possible with the support and collaboration of the Building Trades of Alberta , Canada’s Building Trades Unions , Dassault Systèmes , DHL Express , MaRS , Ikos Consulting , REC Architecture , and SADE Engineering .
About TransPod Inc.
TransPod’s goal is to disrupt and redefine commercial transportation between major cities in developed and emerging markets. The startup was founded in 2015 to build the world’s leading tube-transportation system (the TransPod Line ) to connect people, cities, and businesses with high-speed transportation that is affordable and environmentally sustainable. TransPod Inc. is headquartered in Toronto, Canada and has affiliate companies in Alberta, France, and the UAE. Visit www.transpod.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom